Scalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptions

2025-03-13 pharmacology and therapeutics Title + abstract only

Show abstract

ObjectiveIn spite of evidence and recommendations reflecting the importance of pharmacogenomic testing, most prescriptions are still given without testing. We demonstrate the real world implications of the use of testing and evaluate adverse events and outcomes in individuals who did not receive pharmacogenomic testing for clopidogrel. MethodsWe analyzed ~100K individuals with paired EHR and exome sequencing data from population health studies administered at multiple medical centers using the ...

Scalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptions

Predicted journal destinations